republic-os/legislation/us/states/de/151/hb-320.md

type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags

type	title	description	jurisdiction	legislature	session	identifier	citation	classification	subjects	status	primary_sponsors	version_count	action_count	vote_count	first_action	last_action	source	source_identifier	source_url	source_hash	vintage	source_snapshot	retrieved_at	confidence	tags
Bill	AN ACT TO AMEND TITLE 24 RELATING TO PRESCRIBING MEDICATIONS FOR THE TERMINATION OF PREGNANCY.	In 2000, the United States Federal Drug Administration ("FDA") first approved the Risk Evaluation and Mitigation Strategy ("REMS") for Mifeprex; and approved the generic version of Mifeprex, Mifepristone, in 2019. A regimen approved by the FDA in 2016 for Mifeprex and Mifepristone includes the use of Misoprostol. Under the REMS approved by the FDA, healthcare providers who wish to prescribe Mifepristone, Misoprostol, or Mifeprex must complete a Prescriber Agreement before ordering and dispensing the medication. Physicians assistants and advanced practiced registered nurses (APRNs) are healthcare providers who are eligible to prescribe these medications under the REMS. This bill allows physician assistants and advanced practice registered nurses to prescribe medication for the termination of pregnancy including Mifeprex, Mifepristone, and Misoprostol.	us/states/de	Delaware General Assembly	151	HB 320	Delaware HB 320 (151)	bill		enacted	Bryan Townsend Debra Heffernan Kyle Evans Gay Laura V. Sturgeon Melissa Minor-Brown Sarah McBride Sherry Dorsey Walker Valerie Longhurst	1	8	2	2022-03-09	2022-04-28	openstates	ocd-bill/64c81c9f-5b0d-4a48-b359-6c4051d1ec47	https://legis.delaware.gov/BillDetail?LegislationId=79202	3413e5416ce29f91c438118177c3a657acd324d626bd74f748305af10aed5b45	2026-07-01	https://data.openstates.org/daily/2026-07-01/public.pgdump	2026-07-06	reported	legislation bill us-de

Delaware HB 320 (151) — AN ACT TO AMEND TITLE 24 RELATING TO PRESCRIBING MEDICATIONS FOR THE TERMINATION OF PREGNANCY.

In 2000, the United States Federal Drug Administration ("FDA") first approved the Risk Evaluation and Mitigation Strategy ("REMS") for Mifeprex; and approved the generic version of Mifeprex, Mifepristone, in 2019. A regimen approved by the FDA in 2016 for Mifeprex and Mifepristone includes the use of Misoprostol. Under the REMS approved by the FDA, healthcare providers who wish to prescribe Mifepristone, Misoprostol, or Mifeprex must complete a Prescriber Agreement before ordering and dispensing the medication. Physicians assistants and advanced practiced registered nurses (APRNs) are healthcare providers who are eligible to prescribe these medications under the REMS. This bill allows physician assistants and advanced practice registered nurses to prescribe medication for the termination of pregnancy including Mifeprex, Mifepristone, and Misoprostol.

Version chain

The bill's text revisions, in order — the diff chain from filing to enrollment.

1. Bill Text (committee substitute) — source

Votes

• SM — 25–15 (pass) · lower
• SM — 14–7 (pass) · upper

Sponsors

• Bryan Townsend — primary (person)
• Debra Heffernan — primary (person)
• Kyle Evans Gay — primary (person)
• Laura V. Sturgeon — primary (person)
• Melissa Minor-Brown — primary (person)
• Sarah McBride — primary (person)
• Sherry Dorsey Walker — primary (person)
• Valerie Longhurst — primary (person)
• David Bentz — cosponsor (person)
• David P. Sokola — cosponsor (person)
• Edward S. Osienski — cosponsor (person)
• Eric Morrison — cosponsor (person)
• John A. Kowalko — cosponsor (person)
• Kendra Johnson — cosponsor (person)
• Krista Griffith — cosponsor (person)
• Paul S. Baumbach — cosponsor (person)
• Stephanie L. Hansen — cosponsor (person)
• Trey Paradee — cosponsor (person)

Timeline

The legislative action history — every referral, reading, and vote.

• 2022-03-09 Introduced and Assigned to Health & Human Development Committee in House introduction, referral-committee
• 2022-03-16 Reported Out of Committee (Health & Human Development) in House with 5 Favorable, 3 On Its Merits committee-passage, committee-passage-favorable
• 2022-03-24 Passed By House. Votes: 25 YES 15 NO 1 ABSENT passage
• 2022-03-24 Assigned to Health & Social Services Committee in Senate introduction, referral-committee
• 2022-03-31 Re-Assigned to Legislative Oversight & Sunset Committee in Senate introduction, referral-committee
• 2022-04-05 Reported Out of Committee (Legislative Oversight & Sunset) in Senate with 3 Favorable committee-passage, committee-passage-favorable
• 2022-04-07 Passed By Senate. Votes: 14 YES 7 NO passage
• 2022-04-28 Signed by Governor executive-signature

Source

OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/64c81c9f-5b0d-4a48-b359-6c4051d1ec47. Confidence: reported (aggregated from official Delaware legislature records).